search
Back to results

Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine (PCTKA)

Primary Purpose

Postoperative Pain Management, Total Knee Arthroplasty

Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
Pregabalin
Celecoxib
Pregabalin with celecoxib
Placebo
Sponsored by
Chulalongkorn University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain Management focused on measuring Pregabalin, Celecoxib, Intrathecal morphine, Total knee arthroplasty

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients between 50-75 years of age
  • Patients with an American Society of Anesthesiologists physical status of I to III
  • Patients scheduled for primary TKA with a diagnosis of osteoarthritis under spinal anesthesia

Exclusion Criteria:.

  • Patients had a known allergy to any of the medications being used
  • a history of drug or alcohol abuse
  • a history of taking chronic pain medications (ie, show-release preparations of opioids, given that morphine consumption was the primary outcome)
  • a history of taking pregabalin or gabapentin / non-steroidal anti-inflammatory drugs / COX-2 inhibitors
  • a psychiatric disorder
  • a history of impaired renal function (Cr > 1.5 mg/dl), peptic ulcer, asthma, thrombotic cerebrocardiovascular diseases, uncontrolled hypertension
  • a history of contraindication for spinal anesthesia
  • a history of bleeding tendency
  • pregnancy
  • unable or unwilling to use patient - controlled analgesic (PCA)

Sites / Locations

  • Supranee Niruthisard

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Pregabalin

Celecoxib

Pregabalin with celecoxib

Placebo

Arm Description

Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg

Outcomes

Primary Outcome Measures

24-hour cumulative morphine consumption
The time to first morphine requirement will be recorded The cumulative morphine consumption will be recorded at the end of surgery and 2-h, 6-h, 10-h, 24-h, and 48-h postoperatively Visual analog scale (VAS) pain scores at rest will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively Visual analog scale (VAS) pain scores when on movement will be assessed at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively

Secondary Outcome Measures

Anxiety scores (VAS), patients' satisfaction
Anxiety scores will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively; 24-h and 48-h patients' satisfaction (0-10,0=dissatisfied and 10= very satisfied)

Full Information

First Posted
April 26, 2011
Last Updated
August 2, 2011
Sponsor
Chulalongkorn University
Collaborators
Bhumibol Adulyadej Hospital, King Chulalongkorn Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01344213
Brief Title
Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine
Acronym
PCTKA
Official Title
Comparison of Analgesic Efficacy Among Pregabalin, Celecoxib, Pregabalin With Celecoxib and Placebo After Total Knee Arthroplasty Under Intrathecal Morphine
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Chulalongkorn University
Collaborators
Bhumibol Adulyadej Hospital, King Chulalongkorn Memorial Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate whether pregabalin and/or celecoxib could improve analgesic efficacy of intrathecal morphine for patients after total knee arthroplasty.
Detailed Description
A single-dose spinal anesthesia combining with morphine for total knee arthroplasty (TKA) is a simple, economical anesthetic technique commonly used in our hospital. Still some patients could not get effective postoperative pain control. Pregabalin, an anticonvulsant, has been shown to reduce acute pain after molar extraction, laparoscopic cholecystectomy, and reduce postoperative morphine requirement after total hip arthroplasty, and celecoxib, a selective cyclo-oxygenase (COX) - 2 inhibitor, with perioperative prescription is successfully reduces pain score and opioid consumption after TKA under spinal anesthesia alone. However, no clinical study has yet investigated whether preoperative single-dose of pregabalin, celecoxib or in combination compared to placebo can improve analgesic efficacy of intrathecal morphine after TKA. The primary objective of this study was to evaluate whether these medications could reduce pain scores at rest / when movement and morphine requirement after TKA under spinal anesthesia with intrathecal morphine. Secondary outcome assessed include adverse effects, anxiety score and patients' satisfaction score.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain Management, Total Knee Arthroplasty
Keywords
Pregabalin, Celecoxib, Intrathecal morphine, Total knee arthroplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pregabalin
Arm Type
Active Comparator
Arm Description
Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Arm Title
Celecoxib
Arm Type
Active Comparator
Arm Description
Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Arm Title
Pregabalin with celecoxib
Arm Type
Active Comparator
Arm Description
Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
Intervention Type
Drug
Intervention Name(s)
Pregabalin
Other Intervention Name(s)
Pregabalin: Lyrica
Intervention Description
Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Intervention Type
Drug
Intervention Name(s)
Celecoxib
Other Intervention Name(s)
Celecoxib: Celebrex
Intervention Description
Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Intervention Type
Drug
Intervention Name(s)
Pregabalin with celecoxib
Other Intervention Name(s)
Pregabalin: Lyrica, Celecoxib: Celebrex
Intervention Description
Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo: sugar capsule
Intervention Description
Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
Primary Outcome Measure Information:
Title
24-hour cumulative morphine consumption
Description
The time to first morphine requirement will be recorded The cumulative morphine consumption will be recorded at the end of surgery and 2-h, 6-h, 10-h, 24-h, and 48-h postoperatively Visual analog scale (VAS) pain scores at rest will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively Visual analog scale (VAS) pain scores when on movement will be assessed at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Secondary Outcome Measure Information:
Title
Anxiety scores (VAS), patients' satisfaction
Description
Anxiety scores will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively; 24-h and 48-h patients' satisfaction (0-10,0=dissatisfied and 10= very satisfied)
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients between 50-75 years of age Patients with an American Society of Anesthesiologists physical status of I to III Patients scheduled for primary TKA with a diagnosis of osteoarthritis under spinal anesthesia Exclusion Criteria:. Patients had a known allergy to any of the medications being used a history of drug or alcohol abuse a history of taking chronic pain medications (ie, show-release preparations of opioids, given that morphine consumption was the primary outcome) a history of taking pregabalin or gabapentin / non-steroidal anti-inflammatory drugs / COX-2 inhibitors a psychiatric disorder a history of impaired renal function (Cr > 1.5 mg/dl), peptic ulcer, asthma, thrombotic cerebrocardiovascular diseases, uncontrolled hypertension a history of contraindication for spinal anesthesia a history of bleeding tendency pregnancy unable or unwilling to use patient - controlled analgesic (PCA)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Supranee Niruthisard, BSc, MD
Organizational Affiliation
King Chulalongkorn Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Supranee Niruthisard
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand

12. IPD Sharing Statement

Learn more about this trial

Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine

We'll reach out to this number within 24 hrs